🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT06803537
Active, not recruiting Not applicable

Three-Year Clinical Performance of Fiber-reinforced Versus Indirect Resin Composite Posterior Restorations

NCT06803537 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2022-01-01
Last updated
2025-05-11

Condition(s) studied

Occlusal CariesProximal Caries

Investigational drug(s) / intervention(s)

Fiber-reinforced compositeindirect lab compositeConventional resin composite

Fiber-reinforced composite: short fiber-reinforced composite used as base covered by conventional composite

indirect lab composite: indirect lab processed resin composite inlay restorations

Conventional resin composite: conventional microhybrid resin composite posterior restorations

Study summary

This study aimed to perform a comparison between the clinical performance of short fiber-reinforced composite and indirect lab composite restorations in posterior dentition.

Eligibility

Sex
ALL
Min age
20 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 20-35 year from both genders. 2. Good oral hygiene: patients with low and moderate caries risk (according to Caries management by caries risk assessment CAMBRA sheets) were enrolled in this study. 3. The visual examination should reveal the presence of a minimum of three primary occlusal or proximal caries (Black Class I and II) with a severity score of 4 or 5 according to the International Caries Detection and Assessment System (ICDAS). 4. The carious teeth must exhibit vitality and do not display periapical radiolucency as evaluated by periapical radiography. 5. The selected teeth must be under stable occlusion. Exclusion Criteria: 1. Uncontrolled systemic disease 2. Extremely poor oral hygiene 3. Chronic periodontitis 4. Heavy bruxism 5. Cavities with a buccolingual width exceeding two-thirds of the intercuspal distance or requiring cusp covering. 6. Patients undergoing orthodontic procedures. 7. Patients unable to attend the scheduled recall appointments.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Mansoura university Al Mansurah Dakahlia Governorate

More Mansoura University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06803537 on ClinicalTrials.gov ↗ ← All trials in Egypt